

<!--Vintage Filings Powered By P3XBRL http://www.p3xbrl.com-->
<!--version 4.1.21 -->
<!--produced on 2012-11-05 @ 12:37 PM-->
<xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plx="http://www.protalix.com/20120930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:ISO4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20120930.xsd" />
  <dei:AmendmentFlag id="AmendmentFlag.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="CurrentFiscalYearEndDate.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="DocumentFiscalPeriodFocus.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="DocumentFiscalYearFocus.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="DocumentPeriodEndDate.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">2012-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="DocumentType.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey id="EntityCentralIndexKey.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">0001006281</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="EntityCommonStockSharesOutstanding.690.0.0.0.0.0.0" contextRef="as-of-2012-11-04.690.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">93465169</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory id="EntityFilerCategory.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="EntityRegistrantName.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">PROTALIX BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:TradingSymbol id="TradingSymbol.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">PLX</dei:TradingSymbol>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">72000</plx:CashlessExerciseOfStockOptions>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12000</plx:CashlessExerciseOfStockOptions>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.691.20890.999.0.0.0.0" contextRef="as-of-2012-09-30.691.0.20890.999.0.0.0.0" unitRef="UPure" decimals="1">0.4</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.691.20891.999.0.0.0.0" contextRef="as-of-2012-09-30.691.0.20891.999.0.0.0.0" unitRef="UPure" decimals="1">0.6</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2772000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2698000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5655000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5163000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1963000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1422000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">821000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1477000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:MilestonePayment id="MilestonePayment.693.20883.4951.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20883.4951.0.0.0.0" unitRef="USD" decimals="-5">25000000</plx:MilestonePayment>
  <plx:NatureOfOperationsPolicyTextBlock id="NatureOfOperationsPolicyTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;1.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Operation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On May 1, 2012, the U.S. Food and Drug Administration (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;FDA&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;) approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer Agreement&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;). The Company, through Protalix Ltd., markets ELELYSO in Israel.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States, which was recorded as revenue during the period in which it was received. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits and losses related to commercialization efforts in Israel. &lt;font style="COLOR: black"&gt;In calculating the net profits under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold&lt;/font&gt;.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for Brazil and other countries. The European Commission issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union. This decision is an endorsement of the European Medicines Agency&amp;#39;s Committee for Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV&lt;sup&gt;&amp;reg;&lt;/sup&gt;, Shire plc&amp;#39;s Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, and are anticipated to be treated on a commercial basis in Israel shortly. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. [Notwithstanding the EC&amp;#39;s decision not to approve the market authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, is prepared to continue to supply taliglucerase alfa as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities.] In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;2.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Liquidity and Financial Resources&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to the FDA approval of taliglucerase alfa, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <plx:NumberOfSubsidiaries id="NumberOfSubsidiaries.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="Entity" decimals="0">2</plx:NumberOfSubsidiaries>
  <plx:OtherGainsLosses id="OtherGainsLosses.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">678000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3745000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1666000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-235000</plx:OtherGainsLosses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25328000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20650000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">22062000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23508000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6363000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7918000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.706.22155.344.0.0.0.0" contextRef="as-of-2012-07-16.706.0.22155.344.0.0.0.0" unitRef="USD" decimals="-3">8580000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.707.22155.344.1817.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0" unitRef="Month" decimals="0">24</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.707.22155.344.1817.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0" unitRef="Installment" decimals="0">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.707.22155.344.22161.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.22161.1319.0.0" unitRef="Installment" decimals="0">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.693.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">60000</plx:SupplementalOfferingAndStockIssuanceCosts>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">11444000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7540000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4427000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5032000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4025000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1374000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.693.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">4217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.694.461.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1780000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1410000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.693.4381.1063.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.4381.1063.0.0.0.0" unitRef="USD" decimals="-3">3690000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.694.4381.1063.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.4381.1063.0.0.0.0" unitRef="USD" decimals="-3">348000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.695.4381.1063.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.4381.1063.0.0.0.0" unitRef="USD" decimals="-3">1247000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.696.4381.1063.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.4381.1063.0.0.0.0" unitRef="USD" decimals="-3">92000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.693.2354.1063.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.2354.1063.0.0.0.0" unitRef="USD" decimals="-3">2155000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.694.2354.1063.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.2354.1063.0.0.0.0" unitRef="USD" decimals="-3">382000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.695.2354.1063.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.2354.1063.0.0.0.0" unitRef="USD" decimals="-3">840000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.696.2354.1063.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.2354.1063.0.0.0.0" unitRef="USD" decimals="-3">117000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.693.26156.1063.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.26156.1063.0.0.0.0" unitRef="USD" decimals="-3">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.694.26156.1063.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.26156.1063.0.0.0.0" unitRef="USD" decimals="-3">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.695.26156.1063.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.26156.1063.0.0.0.0" unitRef="USD" decimals="-3">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.696.26156.1063.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.26156.1063.0.0.0.0" unitRef="USD" decimals="-3">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.693.26237.560.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.26237.560.0.0.0.0" unitRef="UShares" decimals="0">7169035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.694.26237.560.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.26237.560.0.0.0.0" unitRef="UShares" decimals="0">7498026</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.695.26237.560.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.26237.560.0.0.0.0" unitRef="UShares" decimals="0">7508240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.696.26237.560.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.26237.560.0.0.0.0" unitRef="UShares" decimals="0">7428201</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets id="Assets.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">77378000</us-gaap:Assets>
  <us-gaap:Assets id="Assets.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">51805000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="AssetsCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">59580000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="AssetsCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">32491000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="BasisOfAccountingPolicyPolicyTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;GAAP&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2011, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2011 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;1.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Operation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On May 1, 2012, the U.S. Food and Drug Administration (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;FDA&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;) approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer Agreement&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;). The Company, through Protalix Ltd., markets ELELYSO in Israel.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits and losses related to commercialization efforts in Israel. &lt;font style="COLOR: black"&gt;In calculating the net profits under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold&lt;/font&gt;.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for Brazil and other countries. The European Commission issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union. This decision is an endorsement of the European Medicines Agency&amp;#39;s Committee for Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV&lt;sup&gt;&amp;reg;&lt;/sup&gt;, Shire plc&amp;#39;s Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, and are anticipated to be treated on a commercial basis in Israel shortly. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. Notwithstanding the EC&amp;#39;s decision not to approve the market authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, will continue to supply taliglucerase alfa as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities. In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;2.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Liquidity and Financial Resources&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to the FDA approval of taliglucerase alfa, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;GAAP&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2011, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2011 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;p style="TEXT-INDENT: -17.85pt; MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 36pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 17.85pt"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s common stock, par value $.001 per share (the "Common Stock"), outstanding for each period.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Shares of restricted Common Stock and the shares of Common Stock underlying outstanding options of the Company were not included in the calculation of diluted LPS because the effect would be anti-dilutive.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Diluted LPS does not include 7,498,026 and 7,169,035 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the nine months ended September 30, 2011 and 2012, respectively, and 7,428,201 and 7,508,240 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the three months ended September 30, 2011 and 2012, respectively.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50216000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.697.0.0.0.0.0.0" contextRef="as-of-2010-12-31.697.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">35900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.698.0.0.0.0.0.0" contextRef="as-of-2011-09-30.698.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">34564000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23215000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1336000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.691.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.692.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.698.0.0.0.0.0.0" contextRef="as-of-2011-09-30.698.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.698.0.0.0.0.0.0" contextRef="as-of-2011-09-30.698.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.710.0.0.0.0.0.0" contextRef="as-of-2012-02-22.710.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">5175000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CostOfRevenue id="CostOfRevenue.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6966000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1130000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2367000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">220000</us-gaap:CostOfRevenue>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4564000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6121000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">47499000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50923000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1134000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1043000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">-0.033</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="1">-0.1</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock id="EarningsPerSharePolicyTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 17.85pt"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s common stock, par value $.001 per share (the "Common Stock"), outstanding for each period.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Shares of restricted Common Stock and the shares of Common Stock underlying outstanding options of the Company were not included in the calculation of diluted LPS because the effect would be anti-dilutive.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Diluted LPS does not include 7,498,026 and 7,169,035 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the nine months ended September 30, 2011 and 2012, respectively, and 7,428,201 and 7,508,240 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the three months ended September 30, 2011 and 2012, respectively.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-113000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-170000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">264000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">57000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">81000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-108000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-14000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-156000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="GainLossOnSaleOfPropertyPlantEquipment.693.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="GainLossOnSaleOfPropertyPlantEquipment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7353000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5314000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2220000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1526000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit id="GrossProfit.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27410000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1149000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3023000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">677000</us-gaap:GrossProfit>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">369000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4388000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2099000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2810000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-4981000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-991000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1779000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-762000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:InventoryDisclosureTextBlock id="InventoryDisclosureTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 2 - INVENTORIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Inventory at September 30, 2012 and December 31, 2011 consisted of the following:&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;September 30,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 74%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,294&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;298&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 466&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2,058&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="COLOR: black"&gt;Prior to the FDA&amp;#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses&lt;/font&gt;. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes all manufacturing costs associated with taliglucerase alfa.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="InventoryFinishedGoodsNetOfReserves.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">466000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="InventoryFinishedGoodsNetOfReserves.692.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InventoryNet id="InventoryNet.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2058000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="InventoryNet.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">279000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="InventoryRawMaterialsNetOfReserves.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1294000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="InventoryRawMaterialsNetOfReserves.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">279000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="InventoryWorkInProcessNetOfReserves.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">298000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="InventoryWorkInProcessNetOfReserves.692.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:Liabilities id="Liabilities.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">72606000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Liabilities.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">77882000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">77378000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">51805000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20435000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">18693000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">52171000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">59189000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2794000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6566000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26424000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20913000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1910000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5121000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1186000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-16958000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1741000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-27616000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5479000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-8875000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.693.4458.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-1741000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.694.4458.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-27616000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2005000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-27673000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5560000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-8767000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3281000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3837000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">122000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsOfStockIssuanceCosts id="PaymentsOfStockIssuanceCosts.709.0.0.0.0.0.0" contextRef="from-2012-02-01-to-2012-02-29.709.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1780000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1817000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5001000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1878000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1700000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">24000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">218000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">115000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.704.0.0.0.0.0.0" contextRef="from-2009-12-01-to-2012-09-30.704.0.0.0.0.0.0.0" unitRef="USD" decimals="-5">60000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.693.20882.4951.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20882.4951.0.0.0.0" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="ProceedsFromIssuanceOfCommonStock.709.0.0.0.0.0.0" contextRef="from-2012-02-01-to-2012-02-29.709.0.0.0.0.0.0.0" unitRef="USD" decimals="0">25388000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ProceedsFromSaleOfPropertyPlantAndEquipment.693.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ProceedsFromSaleOfPropertyPlantAndEquipment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1096000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">263000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.693.20907.3555.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20907.3555.0.0.0.0" unitRef="USD" decimals="-3">1137000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.1877.21244.3555.21242.5007.0.0" contextRef="from-2012-10-01-to-2012-11-30.1877.0.21244.3555.21242.5007.0.0" unitRef="USD" decimals="-3">5187000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16664000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">18271000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27717000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">28671000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8326000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9340000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:Revenues id="Revenues.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">33698000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6024000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3724000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1132000</us-gaap:Revenues>
  <us-gaap:SaleOfStockPricePerShare id="SaleOfStockPricePerShare.710.0.0.0.0.0.0" contextRef="as-of-2012-02-22.710.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">5.25</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="ScheduleOfInventoryCurrentTableTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;September 30,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 74%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,294&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;298&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 466&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2,058&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6065000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">730000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.695.3865.344.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.3865.344.0.0.0.0" unitRef="USD" decimals="-3">3900000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.1772.3865.344.0.0.0.0" contextRef="from-2012-04-01-to-2012-06-30.1772.0.3865.344.0.0.0.0" unitRef="USD" decimals="-3">3900000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.707.22155.344.1817.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.707.22155.344.22161.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.22161.1319.0.0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.695.3865.344.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.3865.344.0.0.0.0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.1772.3865.344.0.0.0.0" contextRef="from-2012-04-01-to-2012-06-30.1772.0.3865.344.0.0.0.0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.707.22155.344.1817.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0" unitRef="UShares" decimals="0">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.707.22155.344.22161.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.22161.1319.0.0" unitRef="UShares" decimals="0">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.706.22155.344.1817.1319.0.0" contextRef="as-of-2012-07-16.706.0.22155.344.1817.1319.0.0" unitRef="UShares" decimals="0">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharesOutstanding id="SharesOutstanding.691.1033.4957.0.0.0.0" contextRef="as-of-2012-09-30.691.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">93461341</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.692.1033.4957.0.0.0.0" contextRef="as-of-2011-12-31.692.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">85630157</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.697.1033.4957.0.0.0.0" contextRef="as-of-2010-12-31.697.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">81248472</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.698.1033.4957.0.0.0.0" contextRef="as-of-2011-09-30.698.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">85598517</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="StockholdersEquity.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4772000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-26077000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.697.0.0.0.0.0.0" contextRef="as-of-2010-12-31.697.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-11323000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.698.0.0.0.0.0.0" contextRef="as-of-2011-09-30.698.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-17353000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.691.1033.4957.0.0.0.0" contextRef="as-of-2012-09-30.691.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.692.1033.4957.0.0.0.0" contextRef="as-of-2011-12-31.692.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.697.1033.4957.0.0.0.0" contextRef="as-of-2010-12-31.697.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">81000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.698.1033.4957.0.0.0.0" contextRef="as-of-2011-09-30.698.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.691.461.4957.0.0.0.0" contextRef="as-of-2012-09-30.691.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">178397000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.692.461.4957.0.0.0.0" contextRef="as-of-2011-12-31.692.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">145814000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.697.461.4957.0.0.0.0" contextRef="as-of-2010-12-31.697.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">124044000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.698.461.4957.0.0.0.0" contextRef="as-of-2011-09-30.698.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">145625000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.691.4458.4957.0.0.0.0" contextRef="as-of-2012-09-30.691.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-173718000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.692.4458.4957.0.0.0.0" contextRef="as-of-2011-12-31.692.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-171977000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.697.4458.4957.0.0.0.0" contextRef="as-of-2010-12-31.697.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-135448000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.698.4458.4957.0.0.0.0" contextRef="as-of-2011-09-30.698.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-163064000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="StockholdersEquityNoteDisclosureTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 3 - STOCK TRANSACTIONS&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 49.65pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 21.25pt"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td style="COLOR: black"&gt;On February 22, 2012, the Company issued and sold 5,175,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.25 per share. The net proceeds to the Company were approximately $25,388,000 (net of underwriting commissions and issuance costs of approximately $1,780,000).&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 49.65pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black; WIDTH: 21.25pt"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;font style="COLOR: black"&gt;During the nine months ended September 30, 2012, the Company issued a total of&lt;/font&gt; 1,156,184 &lt;font style="COLOR: black"&gt;shares of Common Stock in connection with the exercise of a total of&lt;/font&gt; 1,156,184 &lt;font style="COLOR: black"&gt;options by certain officers and employees of the Company. The Company received aggregate cash proceeds equal to approximately $&lt;/font&gt;1,137,000 &lt;font style="COLOR: black"&gt;in connection with such exercises.&lt;/font&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 49.65pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black; WIDTH: 21.25pt"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;font style="COLOR: black"&gt;Following FDA&lt;/font&gt; approval of taliglucerase alfa on May 1, 2012&lt;font style="COLOR: black"&gt;, the Company started recognizing compensation costs in relation to performance-based awards that were granted in February 2010 to certain officers and employees of the Company, which vest over a three-year period commencing upon the FDA&amp;#39;s approval of&lt;/font&gt; taliglucerase alfa&lt;font style="COLOR: black"&gt;. During the second and third quarter of 2012, the Company recorded an expense in the amount of approximately $3,900,000 for the cumulative period from the date of grant.&lt;/font&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 49.65pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black; WIDTH: 21.25pt"&gt;&lt;strong&gt;d.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;On July 16, 2012, the Company&amp;#39;s Board of Directors approved the grant of 1,500,000 shares of restricted Common Stock to its officers and certain other employees. Of such restricted shares, 1,100,000 of the shares were issued to the Company&amp;#39;s named executive officers and vest in 16 equal, quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a 24-month lock-up period, commencing upon the applicable vesting dates. Immediately and automatically in the event of a Change in Control, as such term is defined in the Company&amp;#39;s 2006 Stock Incentive Plan, as amended, all of the shares of restricted Common Stock issued to the named executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining 400,000 shares of restricted Common Stock were issued to other employees of the Company and vest in 12 equal, quarterly increments over a three-year period, commencing upon the date of grant. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $8,580,000.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">1500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="StockIssuedDuringPeriodSharesShareBasedCompensation.693.20907.3555.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20907.3555.0.0.0.0" unitRef="UShares" decimals="0">1156184</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">1156184</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">350045</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.1877.21244.3555.21242.5007.0.0" contextRef="from-2012-10-01-to-2012-11-30.1877.0.21244.3555.21242.5007.0.0" unitRef="UShares" decimals="0">3828</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.693.20907.3555.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20907.3555.0.0.0.0" unitRef="UShares" decimals="0">1156184</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.693.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">1847000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1848000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.694.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.693.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">25383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.694.461.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">20586000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25388000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20590000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.694.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.693.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">1136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.694.461.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">265000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1137000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">266000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:SubsequentEventsTextBlock id="SubsequentEventsTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 4 - SUBSEQUENT EVENTS&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; During October and November 2012, the Company issued a total of 3,828 shares of Common Stock in connection with the exercise of options to purchase 3,828 shares of Common Stock by an employee of the Company. The aggregate cash proceeds in connection with the exercise of the options were $5,187.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">90491421</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">84351420</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">91929445</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">85585777</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <xbrli:unit id="UShares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>ISO4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UPure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Entity">
    <xbrli:measure>plx:Entity</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Installment">
    <xbrli:measure>plx:Installment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Month">
    <xbrli:measure>plx:Month</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>ISO4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="from-2012-10-01-to-2012-11-30.1877.0.21244.3555.21242.5007.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionExerciseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.4381.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.3865.344.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.26237.560.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.26156.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CostOfRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.2354.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-07-31.707.0.22155.344.22161.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockCompensationPlanAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockCompensationPlanAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-04-01-to-2012-06-30.1772.0.3865.344.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-02-01-to-2012-02-29.709.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.4381.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.26237.560.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.26156.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CostOfRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.2354.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.20907.3555.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeeAndNonemployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.20883.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.20882.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.4381.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.26237.560.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.26156.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CostOfRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.2354.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.4381.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.26237.560.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.26156.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CostOfRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.2354.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-12-01-to-2012-09-30.704.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-12-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-11-04.690.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-11-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.20891.999.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:PfizerIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.20890.999.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-07-16.706.0.22155.344.1817.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockCompensationPlanAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-07-16.706.0.22155.344.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockCompensationPlanAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-02-22.710.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.692.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.692.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.692.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.692.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-09-30.698.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-09-30.698.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-09-30.698.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-09-30.698.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.697.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.697.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.697.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.697.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#CostOfRevenue.693.0.0.0.0.0.0" xlink:label="CostOfRevenue.693.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="CostOfRevenue.693.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 220 0 220 0</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="CostOfRevenue.693.0.0.0.0.0.0_loc" xlink:to="CostOfRevenue.693.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#CostOfRevenue.694.0.0.0.0.0.0" xlink:label="CostOfRevenue.694.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="CostOfRevenue.694.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 220 0 220 0</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="CostOfRevenue.694.0.0.0.0.0.0_loc" xlink:to="CostOfRevenue.694.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#CostOfRevenue.695.0.0.0.0.0.0" xlink:label="CostOfRevenue.695.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="CostOfRevenue.695.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 220 0 220 0</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="CostOfRevenue.695.0.0.0.0.0.0_loc" xlink:to="CostOfRevenue.695.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#CostOfRevenue.696.0.0.0.0.0.0" xlink:label="CostOfRevenue.696.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="CostOfRevenue.696.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 220 0 220 0</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="CostOfRevenue.696.0.0.0.0.0.0_loc" xlink:to="CostOfRevenue.696.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#ResearchAndDevelopmentExpense.693.0.0.0.0.0.0" xlink:label="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 1,247 92 3,690 348</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0_loc" xlink:to="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#ResearchAndDevelopmentExpense.694.0.0.0.0.0.0" xlink:label="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 1,247 92 3,690 348</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0_loc" xlink:to="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#ResearchAndDevelopmentExpense.695.0.0.0.0.0.0" xlink:label="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 1,247 92 3,690 348</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0_loc" xlink:to="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#ResearchAndDevelopmentExpense.696.0.0.0.0.0.0" xlink:label="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 1,247 92 3,690 348</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0_loc" xlink:to="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#GeneralAndAdministrativeExpense.693.0.0.0.0.0.0" xlink:label="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 840 117 2,155 382 </link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0_loc" xlink:to="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#GeneralAndAdministrativeExpense.694.0.0.0.0.0.0" xlink:label="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 840 117 2,155 382 </link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0_loc" xlink:to="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#GeneralAndAdministrativeExpense.695.0.0.0.0.0.0" xlink:label="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 840 117 2,155 382 </link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0_loc" xlink:to="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#GeneralAndAdministrativeExpense.696.0.0.0.0.0.0" xlink:label="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 840 117 2,155 382 </link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0_loc" xlink:to="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#SharesOutstanding.691.1033.4957.0.0.0.0" xlink:label="SharesOutstanding.691.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="SharesOutstanding.691.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="SharesOutstanding.691.1033.4957.0.0.0.0_loc" xlink:to="SharesOutstanding.691.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#SharesOutstanding.692.1033.4957.0.0.0.0" xlink:label="SharesOutstanding.692.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="SharesOutstanding.692.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="SharesOutstanding.692.1033.4957.0.0.0.0_loc" xlink:to="SharesOutstanding.692.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#SharesOutstanding.697.1033.4957.0.0.0.0" xlink:label="SharesOutstanding.697.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="SharesOutstanding.697.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="SharesOutstanding.697.1033.4957.0.0.0.0_loc" xlink:to="SharesOutstanding.697.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
    
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  
   
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#SharesOutstanding.698.1033.4957.0.0.0.0" xlink:label="SharesOutstanding.698.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="SharesOutstanding.698.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="SharesOutstanding.698.1033.4957.0.0.0.0_loc" xlink:to="SharesOutstanding.698.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
</xbrl>